MDR Extension Regulation (EU) 2023/607

Regulation (EU) 2023/607 is a targeted amendment to the EU Medical Device Regulation (MDR) designed to avoid supply disruptions while preserving the MDR’s safety bar. It extends transitional timeframes for legacy devices with valid MDD/AIMDD certificates and formally deletes the EU-wide sell-off deadlines so that already placed devices can continue to be made available without a fixed end date.

The core intent is pragmatic: give manufacturers and notified bodies breathing room to complete MDR conformity assessments amid capacity constraints, without creating safety loopholes. The extension is not automatic. It is conditional on having an MDR-grade quality management system, timely engagement with a notified body, and continuous vigilance and market surveillance aligned to MDR obligations.

In practice, 2023/607 creates a dual focus for regulatory teams. You must sustain compliant production of legacy devices under MDD/AIMDD terms while concurrently executing the MDR transition plan on a fixed schedule. This requires tight control of change, robust post-market performance data, and evidence that no significant changes in design or intended purpose are introduced during the transition.

The measure sits squarely within the MDR framework, complementing core requirements in Articles 10, 61, and 120 and preserving the EU’s risk-based approach. It does not relax General Safety and Performance Requirements, clinical evaluation expectations, or economic operator duties under the MDR.

The extension applies to legacy devices, meaning devices covered by valid certificates issued under the Active Implantable Medical Devices Directive (AIMDD) or the Medical Devices Directive (MDD) that continue to be placed on the market under MDR transitional provisions. It also captures certain Class I devices that became up-classified under the MDR and therefore require notified body involvement for the first time.

Eligibility is conditioned on the device remaining compliant with its applicable directive and on the absence of significant changes in design or intended purpose. Manufacturers must also have an MDR Article 10–grade quality management system in place by a set milestone and must have initiated MDR conformity assessment with a notified body within fixed dates. Vigilance and post-market surveillance obligations follow the MDR for these legacy devices throughout the extension period.

Regulation (EU) 2023/607 does not change the substantive MDR bar for new or fully transitioned devices. Those devices remain subject to the MDR in full. The extension affects only the timing for placing eligible legacy devices on the market and the commercial availability of units already in the supply chain, without softening safety expectations. Teams should read the amendment in the context of the baseline EU MDR and national market-surveillance practices.

For companies operating in multiple jurisdictions, the EU extension interacts with third-country regimes but does not govern them. The UK’s arrangements are separate; see the UKCA medical device transition for Great Britain. Inside the EU, coordination with hospital procurement and distributors remains essential to avoid unintended lapses in labeling or lot-level availability as the transition advances.

Regulation (EU) 2023/607 extends the latest dates by which eligible legacy devices may be placed on the market. The specific deadlines vary by risk class. After these dates, only MDR-conforming devices may be newly placed. Devices already placed in the supply chain may continue to be made available as the sell-off deadline has been removed.

Use these dates to anchor internal transition plans, NB application milestones, and last-time-buy communications. Align supply and change-control cutoffs well ahead of the final placing-on-the-market windows for each class to protect continuity of care and minimize obsolescence risk.

Remember that “placing on the market” is a legal act tied to making a device available for the first time. Manufacturing or shipment timing alone does not suffice; your ERP and documentation must evidence the legal placing date against the extended deadlines.

The extension is conditional, not automatic. Manufacturers must maintain directive-level compliance for the legacy device, keep the device free of significant changes in design or intended purpose, and meet explicit MDR transition milestones tied to quality management, notified body engagement, and safety monitoring. Authorities retain the power to intervene if a device presents an unacceptable risk.

Plan against fixed calendars. The Commission signaled three time-bound steps: implement an MDR-grade QMS, lodge a formal MDR application with a notified body, and execute a written agreement with that body within prescribed dates. Failure to hit these gates jeopardizes reliance on extended validity for legacy certificates.

1. Implement an MDR Article 10(9)–compliant QMS by 26 May 2024, documented and operating.
2. Submit a formal MDR conformity assessment application to a notified body by 26 May 2024.
3. Conclude a written agreement with the notified body by 26 September 2024.
4. Operate MDR-aligned post-market surveillance and vigilance for legacy devices throughout the transition.
5. Introduce no significant change in design or intended purpose; only strictly necessary, non-significant changes are allowed.

Teams should connect these regulatory gates to internal governance: management review cadence, resource allocation, and readiness of clinical and performance evidence. Consider a pre-submission gap analysis against the MDR Annexes and align notified body scheduling to realistic dossier maturity.

Start with an integrated plan that binds regulatory milestones to production, supply, and commercial realities. Map MDR evidence generation to device risk and clinical context, and time dossier freezes before class-dependent deadlines. Treat the extended dates as buffers, not targets.

Notified body capacity remains the pacing factor for many manufacturers. Strengthen your readiness by tightening your technical documentation to MDR Annex II and III expectations and pre-validating clinical evaluation logic. Use the Commission’s timelines as the outer boundary, but schedule NB submissions months earlier to allow for rounds of questions.

During the extension, legacy devices must run under MDR-level post-market surveillance. Harmonize trending, complaints, and vigilance submissions across legacy and MDR-certified SKUs to avoid duplicate infrastructures. Monitor EUDAMED module go-lives and plan data onboarding ahead of EUDAMED go-live 2026. For structure and checklists, see EU MDR technical documentation readiness and keep your Post-market surveillance system demonstrably effective.

Ensure commercial and supply teams are literate in the legal definition of “placing on the market.” Configure ERP gating so that sales orders that would post a placing date after the applicable class deadline are blocked without MDR certification. Train distributors on the deleted sell-off concept and on their continuing duties to relay vigilance information.

“No significant change” during the extension is a central rule. Substantive changes to design or intended purpose typically trigger MDR conformity immediately. Conversely, purely administrative or maintenance changes, or those necessary to address safety issues without altering intended purpose, are generally acceptable within the legacy regime. Document your rationale meticulously.

Labeling and IFU updates must be handled carefully. Legacy devices may retain directive-era labels, but safety-related updates and vigilance contact data must be current. When a device transitions to MDR certification, apply MDR labeling, including UDI and economic-operator details, at the point of MDR placing on the market, and maintain clear segregation between legacy and MDR stock.

Operationally, link change control to risk management and PMS signals so that safety-driven updates flow to labels and Instructions for Use without crossing into significant-change territory. Use part-numbering and lot controls to prevent commingling of directive and MDR stock and ensure field actions are traceable across both populations.

Train RA, quality, and supply teams to recognize when a change boundary is being approached and to escalate early for notified body input. Clear, contemporaneous documentation of your significance assessment is often the decisive artifact during inspections.

For procedures and work instructions, maintain a dedicated SOP that references your labeling matrix and decision trees. Reinforce shop-floor and warehouse scanning discipline so that downstream partners can distinguish generations reliably. See Instruction for Use (IFU) and consider digital serial- and lot-level controls supported by Traceability.

The 2023/607 amendment is mirrored by adjustments to the IVDR timelines, with the Commission later clarifying a staged approach for IVDs. While the legal texts differ, the policy logic is similar: avoid loss of critical diagnostics and therapies while preserving post-market safety obligations. For IVD planning, align with the staged IVDR transitions and notified body capacity dynamics.

Beyond devices, the EU is building a connected ecosystem for evidence and value assessment. The EU Health Technology Assessment Regulation will progressively affect clinical and economic evidence expectations for certain categories, changing the downstream value narrative even after MDR certification. Regulatory and market-access roadmaps should be coordinated early.

Outside the EU, timelines and acceptance criteria vary. Great Britain follows a different pathway and calendar; EU certificates may be recognized under defined policies, but these are not governed by 2023/607. ISO 13485 remains the quality backbone recognized globally, and aligning your QMS to that standard strengthens both MDR transition and international submissions.

For planning resources and cross-framework alignment, consult the IVDR readiness materials and national guidance where you market your products. Keep a single, global QMS baseline that meets MDR Article 10 expectations and maps directly to ISO 13485 controls so that local supplements remain minimal.

See the IVDR transition extension, EU IVDR readiness, and EU HTA Regulation 2025 for adjacent planning considerations. If you supply Great Britain, track the UKCA medical device transition for parallel obligations.

The most frequent misstep is treating the extension as permission to slow-walk MDR transition. It is not. It is a safety net to prevent shortages while you complete MDR certification. Treat the class deadlines as the outer boundary, and set earlier internal targets to absorb notified body and evidence uncertainties.

A second trap is misunderstanding the deletion of the sell-off deadline. Deleting sell-off does not authorize new placing of non-compliant product after the class deadline. It simply permits continued making available of units that were lawfully placed before the cutoff, subject to market-surveillance controls and vigilance responsiveness.

Significant change thresholds are another source of error. Seemingly small firmware, materials, or specification updates can cross the line if they affect performance or intended purpose. Build a conservative, documented review process with engineering and clinical input, and escalate borderline cases to your notified body before implementation.

Finally, many firms underinvest in distributor training and data flows. Your vigilance and PMS systems must capture signals across all markets where legacy stock is available. Contractual obligations and data-sharing expectations should be explicit and auditable.

Couple these guardrails with supply controls. Use a disciplined last-time-buy process, dual labeling governance for legacy and MDR SKUs, and upstream oversight of critical suppliers. Incorporate Supply chain risk management principles so single-source components do not jeopardize MDR dossier changes or NB scheduling.

A successful 2023/607 program binds governance, evidence, and operations. V5 Ultimate provides a single system of record to run legacy production compliantly while maturing MDR dossiers and managing notified body interactions. It connects shop-floor controls to regulatory evidence so you can prove ongoing compliance during the transition.

Document packages align to MDR Annex II and III structures and stay audit-ready with controlled revisions, e-signatures, and time-stamped change histories. MDR-grade QMS processes, management reviews, and CAPA close the loop with PMS data and field performance trending to demonstrate effectiveness under MDR obligations for legacy devices.

Operational safeguards prevent misplacing after deadlines. Date-aware release controls, SKU segregation, and electronic device history records tie placing-on-the-market logic to your regulatory status. Notifications, dashboards, and supplier collaboration keep your NB milestones and evidence generation on track.